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A cure for HIV infection remains elusive due to the persistence of replication-competent
HIV proviral DNA during suppressive antiretroviral therapy (ART). With the exception of
rare elite or post-treatment controllers of viremia, withdrawal of ART invariably results
in the rebound of viremia and progression of HIV disease. A thorough understanding
of the reservoir is necessary to develop new strategies in order to reduce or eliminate
the reservoir. However, there is significant heterogeneity in the sequence composition,
genomic location, stability, and expression of the HIV reservoir both within and across
individuals, and a majority of proviral sequences are replication-defective. These factors,
and the low frequency of persistently infected cells in individuals on suppressive ART,
make understanding the reservoir and its response to experimental reservoir reduction
interventions challenging. Here, we review the characteristics of the HIV reservoir, state-
of-the-art assays to measure and characterize the reservoir, and how these assays
can be applied to accurately detect reductions in reservoir during efforts to develop
a cure for HIV infection. In particular, we highlight recent advances in the development
of direct measures of provirus, including intact proviral DNA assays and full-length HIV
DNA sequencing with integration site analysis. We also focus on novel techniques to
quantitate persistent and inducible HIV, including RNA sequencing and RNA/gag protein
staining techniques, as well as modified viral outgrowth methods that seek to improve
upon throughput, sensitivity and dynamic range.
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INTRODUCTION
An estimated 40 million people are living with HIV, and over 30 million have died because of it.
The incidence of new HIV infections globally is approximately 2 million each year (GBD 2015
HIV Collaborators, 2016; WHO, 2019). While antiretroviral therapy (ART) can control viremia
and improve health outcomes, durably ART-suppressed HIV seropositive individuals are still at
higher risk for diseases related to immune dysfunction and inflammation compared to uninfected
individuals (Hunt et al., 2016). Moreover, lifelong adherence to ART is required for optimal health
outcomes and is associated with financial burden, drug interactions, and unknown long-term effects
of treatment (Deeks et al., 2017; Devanathan et al., 2019). Further, the stigma associated with HIV
disease contributes to negative health outcomes (Rueda et al., 2016). Therefore, a cure for HIV is of
substantial public health interest.
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However, eliminating HIV infection remains an elusive goal
due to the viral reservoir—HIV proviral DNA in the host
genome of resting CD4+ T lymphocytes and possibly other
cells (Bukrinsky et al., 1991; Chun et al., 1997, 1998; Finzi
et al., 1997; Wong et al., 1997b; Finzi et al., 1999; Ganor
et al., 2019). For the purposes of this review, we define the
viral reservoir as a cell that encodes integrated, replication-
competent virus that can fuel viral rebound after treatment
interruption, even after years of suppressive ART (Eisele and
Siliciano, 2012; Margolis et al., 2016). When referring broadly
to HIV DNA that is integrated but includes both replication-
competent and replication-incompetent HIV, we use the term
persistent HIV (Wang et al., 2018b). On suppressive ART,
transcription of proviral DNA from persistently infected cells
during immune activation or other normal cellular processes can
result in viral gene expression and viral particle release (Shen and
Siliciano, 2008; Pasternak et al., 2013). Whether these particles
are able to establish new infections under suppressive ART is
a historical area of debate (Shen and Siliciano, 2008; Lorenzo-
Redondo et al., 2016; Margolis et al., 2016; Martinez-Picado and
Deeks, 2016); however, the overwhelming majority of evidence
supports the notion that active viral replication does not occur
during suppressive therapy. Rather, (1) long-lived cells infected
prior to ART-initiation and (2) expansion of infected cells
through cell division during suppressive therapy are responsible
for persistence of the reservoir on long-term suppressive ART
(Maldarelli, 2015; Bui et al., 2017; Kearney et al., 2017; Anderson
and Maldarelli, 2018; Mok et al., 2018; Wang et al., 2018a; Bozzi
et al., 2019). Nonetheless, upon cessation of suppressive ART,
there is a rebound of viremia from the reservoir on the timescale
of weeks and in general, progression of HIV disease if ART is not
resumed (Chun et al., 1999; Hamlyn et al., 2012).
Research efforts over the past 30 years have sought to
understand the reservoir in order to facilitate the development
of interventions that could eradicate the reservoir (a cure)
or enable HIV seropositive individuals to maintain suppressed
viremia in the absence of ART (a functional cure) (Deeks
et al., 2016). A central strategy for eradication (cure) is
the use of latency reversal agents (LRAs) to induce proviral
expression in conjunction with a vaccine, antibody, and/or
cellular immunotherapy in order facilitate immune clearance
of virally infected cells (Margolis et al., 2016). With regard
to a functional cure, major strategies include the use of long-
acting broadly neutralizing antibodies (passive immunotherapy),
vaccination (active immunotherapy), modification of host cells to
prevent viral replication (gene therapy), or permanent silencing
of provirus (“block and lock”) (Cillo and Mellors, 2016; Kessing
et al., 2017; Elsheikh et al., 2019).
Common to all of these approaches for a cure or functional
cure is a need for careful characterization and measurement
of the viral reservoir. In recent years, advances in technology
and the HIV cure field have resulted in the development of
an arsenal of assays to characterize and measure the HIV
reservoir. In this review, we first provide an overview of
the characteristics of HIV reservoir—including the cell types
thought to harbor the reservoir, the spectrum of viral expression
within the reservoir, and the diversity of proviruses within the
reservoir. Next, we review standard as well as emerging assays
for measuring the reservoir. Throughout, we discuss ongoing and
future applications of these assays to (1) improve understanding
of the stability of the HIV reservoir and (2) accurately and
reliably detect a reduction in the frequency of the HIV reservoir
in cure research.
THE HIV RESERVOIR: CELL TYPES THAT
HARBOR THE RESERVOIR
Here, we define the HIV reservoir as any cell that can produce
replication-competent virus despite years of suppressive ART
(Eisele and Siliciano, 2012; Margolis et al., 2016). To date, in
humans, resting CD4+ T lymphocytes represent the largest
and most well-characterized viral reservoir. However, there is
mounting evidence from both animal models and human donors
that other cell types may contribute to the total HIV reservoir.
To provide context for our review of assays to measure the
reservoir, we provide a brief overview of the cell types that may
compose the reservoir.
CD4 T Cells
Resting CD4 T cells, defined as CD3+CD4+CD25-CD69-
HLADR-, were the first cells to be identified as a reservoir for
HIV (Chun et al., 1997, 1998; Finzi et al., 1997, 1999; Wong
et al., 1997b). At the time, it was generally not believed that
HIV exhibited a latent stage in its lifecycle, and so the use
of this resting cell population allowed the demonstration of a
definable pool of cells that lacked HIV expression when isolated,
but could be induced (activated) ex vivo to express replication-
competent HIV — hence a definitive proof of the presence of true
virologic latency.
This reservoir in resting CD4 T cells is known to be very
stable with a long half-life (∼44.5 months) (Siliciano et al., 2003;
Crooks et al., 2015). Therefore, to date, these cells represent
the most formidable barrier to cure because of their frequency
and slow decay rate. Within resting CD4 T cells, the HIV
reservoir is most frequently detected in the central memory
compartment (Finzi et al., 1997; Soriano-Sarabia et al., 2014).
Of note, some studies using total CD4 T cells have detected
higher frequencies of persistent HIV in the effector memory
subset (Hiener et al., 2017), whereas others describe the highest
frequency of persistent HIV in the central memory compartment
(Chomont et al., 2009). In addition, replication-competent HIV
has been recovered from naïve T cells and transitional memory
T cells (Chomont et al., 2009; Soriano-Sarabia et al., 2014;
Zerbato et al., 2019). HIV reservoirs have also been detected in
gamma/delta T cells (Soriano-Sarabia et al., 2015) (Figure 1). The
half-life of the reservoir in each of these cell compartments is
little studied, and is complicated by the natural differentiation of
these immune cells across compartments (i.e., central memory
to effector memory). Furthermore, in the case of gamma/delta
T cells, their low frequency and dual function as reservoirs
and immune effectors complicates efforts to understand their
contribution as a stable source of HIV under ART (Soriano-
Sarabia et al., 2015; Garrido et al., 2018). Finally, long-lived CD4+
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FIGURE 1 | Overview of cell types and anatomic sites reported to harbor the latent reservoir. (A) Cell types thought to harbor the HIV reservoir. Cell types with
demonstrated recovery of replication-competent virus (defined as propagating virus in an outgrowth assay) in humans following years of suppressive ART are in bold.
Cell types in regular font represent cells where HIV nucleic acid has been detected by PCR and/or sequencing either in humans or animal models but recovery of
replication-competent virus in humans after years of suppressive ART has not been demonstrated. It is important to note that for many cell types, there has been
very sparse sampling for replication-competent virus. NA, naïve; SCM, stem cell memory; CM, central memory; TM, transitional memory; EM, effector memory; TD,
terminally differentiated; MM, migratory memory; RM, resident memory. (B) Anatomic sites with demonstrated recovery of replication-competent virus in humans
following years of suppressive ART are highlighted in bold. Potential replication-competent anatomic reservoir sites are in regular font. These sites represent
tissues/organs where HIV nucleic acid has been detected either in humans or animal models but recovery of replication-competent virus in humans after years of
suppressive ART has not been demonstrated. It is important to note that for many tissue types, there has been very sparse sampling for replication-competent virus.
Images were derived and modified from Servier Medical Arts under a Creative Commons Attribution 3.0 Unported License.
T memory stem cells may also contribute significantly to the viral
reservoir in some individuals (Buzon et al., 2014).
Non-resting CD4 T cells that express one or more markers
associated with activation (CD25, CD69, and/or HLA-DR) may
also contain persistent, replication-competent HIV; however,
the stability of persistent HIV within these cells remains to
be proven. HIV DNA is enriched in non-resting CD4 T cells
(Chun et al., 2005) and markers of immune activation and
dysfunction are moderately correlated with DNA and RNA
markers of viral persistence in some studies (Chomont et al.,
2009; Hatano et al., 2013; Cockerham et al., 2014). A recent
study demonstrated the recovery of identical gag-pol sequences
from HLA-DR expressing-CD4 T cells over multiple time
points in durably suppressed participants (Lee et al., 2019).
This underscores the importance of interrogating non-resting
CD4 T cells for HIV during suppressive therapy. Whether
virus found in non-resting T cells originated from resting
cells that acquired activation markers, or if some of these
cells later return to the resting state is not well understood.
As most activated T cells die in the contraction phase of
the immune response (Alderson et al., 1995; Swain et al.,
1996; Green et al., 2003; Marrack et al., 2010; McKinstry
et al., 2010), activated T cells likely do not represent a stable
reservoir. However, it is unclear if HLA-DR, CD25, and/or
CD69 expression are always indicators of fully activated T
cells that are destined to die via immune contraction. In
addition, CD25 and/or HLA-DR expressing cells likely represent
a heterogenous population of T regulatory cells and activated T
cells (Simonetta and Bourgeois, 2013; Corneau et al., 2017). Thus,
further evaluation of persistent HIV within these non-resting
cells is warranted.
Functional polarization of CD4 T cells may also influence
reservoir formation and stability. Within the B cell follicle and
in the periphery, T follicular helper (Tfh) cells also represent
an important cell type that harbors replication-competent HIV
(Pallikkuth et al., 2015; Banga et al., 2016). Given the central
role of Tfh cells in HIV replication during active infection,
the reservoir may be highly enriched within tissue Tfh cells
(Banga et al., 2016). In addition, HIV DNA is enriched
in CD4 T cells with Th1/17 and Treg polarizations (Tran
et al., 2008; Kulpa and Chomont, 2015; Sun et al., 2015;
Dunay et al., 2017).
Studies of viremia in individuals on suppressive therapy
(viral “blips” or residual viremia) demonstrate that the residual
viremia is not always representative of the proviruses that
compose the latent reservoir in CD4 T cells from peripheral
blood (Bailey et al., 2006; Sahu et al., 2009; Anderson et al.,
2011). However, this does not exclude the possibility that a
small pool of peripheral blood CD4 T cells is responsible for
residual viremia. Another possibility is that this residual viremia
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may be derived from CD4 T cells in tissues, or other cell
types in tissues.
Other Cell Types
Until recently no study has demonstrated recovery, following
years of suppressive therapy, of replication-competent virus from
any other purified human cell type other than CD4+ T cells.
However, a recent study demonstrated recovery of replication-
competent HIV from macrophages harvested from urethral
tissue of durably ART-suppressed donors (Ganor et al., 2019).
In addition to urethral macrophages, there are several lines of
reasoning and evidence that underscore the need to evaluate
other cell types for HIV reservoir.
Cells from non-lymphoid lineages can be infected and
produce HIV virions during active infection. However, the role
and stability of these cells under suppressive ART is highly
debated. Bone-marrow derived macrophages, as well as yolk-
sac derived microglia and other tissue-resident macrophages
may also represent potential HIV reservoirs (Gomez Perdiguero
et al., 2015; Gama et al., 2018; Wong et al., 2019). Importantly,
there is an increasing appreciation for the ability of tissue
resident macrophages to self-renew and potentially serve as
a long-lived reservoir of replication-competent virus (Gama
et al., 2018; Roszer, 2018; Wong et al., 2019). In addition,
neuroepithelial progenitor-derived astrocytes also harbor HIV
provirus, though the replication competency and potential for
reactivation of this virus in vivo is poorly understood (Al-Harti
et al., 2018; Barat et al., 2018). HIV can infect multipotent
hematopoietic CD34+ progenitor cells; however, in general
during stable therapy detection of HIV DNA in this population
is rare and no recovery of replication-competent virus has been
demonstrated (Carter et al., 2010; Durand et al., 2012; Josefsson
et al., 2012; Sebastian et al., 2017; Zaikos et al., 2018). Similarly,
HIV DNA has been detected rarely in monocytes from durably
suppressed individuals; however, monocytes have a half-life of
days in vivo and do not represent a stable reservoir. Furthermore,
purification of monocytes is complicated by their tendency to
stick to CD4 T cells (Burel et al., 2019; Massanella et al., 2019).
Infectious virus was recovered from placenta-associated mast
cells from women on suppressive ART; however, the period
of ART was on a timescale of months rather than years and
suppression was defined as <400 copies HIV RNA/mL of plasma
(Sundstrom et al., 2007). In all of these cases, however, no
longitudinal study of the viral sequences that would appear
to be replication-competent, or the recovery of virus from
these populations over time, has been demonstrated in any of
these cell types.
While there is a substantial body of evidence supporting
the presence of HIV DNA or RNA in these cell populations,
there has been no detection of replication-competent HIV that
is directly attributable to a non-lymphoid lineage in ART-
suppressed human donors, except for urethral macrophages
(Ganor et al., 2019; Wong et al., 2019). Nevertheless, the finding
of persistent HIV in urethral macrophages despite long-term
ART, demonstration of rebound viremia in humanized myeloid-
only mice, and recovery of replication-competent SIV from brain
macrophages of ART-suppressed macaques underscores the need
to further evaluate non-lymphoid lineage cells as potential
long-lived reservoirs of replication-competent HIV in humans
(Honeycutt et al., 2017; Gama et al., 2018; Ganor et al., 2019).
THE HIV RESERVOIR: ANATOMIC SITES
OF THE RESERVOIR
The majority of studies of the HIV reservoir under suppressive
ART have been in peripheral blood CD4 T cells. While these
studies have yielded key insights into the HIV reservoir, it is
critical to acknowledge that circulating CD4 T cells represent
less than 2% of total body CD4 T cells (Westermann and
Pabst, 1992; Di Mascio et al., 2009). There is an increasing
appreciation for the microenvironment of tissue in the study
of the reservoir of persistent HIV infection, and in the
evaluation of cure or functional cure interventions (Figure 1)
(Barton et al., 2016; Churchill et al., 2016; Wong and Yukl,
2016). This tissue context may include factors such as viral
sequence compartmentalization, variation in viral expression
levels, differential ART penetration, and availability of immune
effector mechanisms to clear infected cells expressing viral RNA
or protein (Fletcher et al., 2014; Deeks et al., 2016; Margolis et al.,
2016; Baxter et al., 2018; van Zyl et al., 2018; Miller et al., 2019;
Pardons et al., 2019).
Detailed HIV reservoir measurements of different tissues are
reviewed elsewhere (Yukl and Wong, 2015; Barton et al., 2016;
Churchill et al., 2016; Wong and Yukl, 2016). For the purposes
of this review, we consider both defined and potential anatomic
reservoir sites (Figure 1) in the context of current and emerging
reservoir assays. Defined anatomic replication-competent HIV
reservoir sites in humans who have been treated with long-
term (years) of fully suppressive ART include CD4 T cells from
peripheral blood and some secondary lymphoid tissues (Siliciano
et al., 2003; Crooks et al., 2015; Sanyal et al., 2018), and recently
the reproductive tract in the form of urethral macrophages
(Ganor et al., 2019). It is critical to note that because of limited
access to human tissue, there is sparse sampling of many tissue
types (i.e., spleen) that undoubtedly harbor CD4 T cells with
replication-competent HIV (Figure 1).
However, there are many long-lived cell types, such as other
tissue resident macrophages in other sites (e.g., microglia),
astrocytes, hematopoietic progenitor cells, among others, in
which HIV DNA or RNA has been detected but replication-
competent HIV has not (Carter et al., 2010; Canaud et al., 2014;
Yukl and Wong, 2015; Al-Harti et al., 2018; Ko et al., 2019; Wong
et al., 2019) (Figure 1). Therefore, we consider tissues with these
cell types as potential reservoir sites. These cell types are found
throughout the body in a variety of different tissues. Again, it
is important to note that the absence of recovery of replication-
competent virus in these tissues does not mean that reservoir does
not exist in these locations. Limited access to human tissues, and
the technical complexities associated with viral outgrowth assays
in these samples limits the sensitivity of studies performed to date
(Churchill et al., 2016; Deeks et al., 2016, 2017; Ganor et al., 2019).
Understanding the composition and frequency of the replication-
competent reservoir across different tissues is a critical issue for
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future cure research, as cure interventions must be assessed by
their effect on the viral reservoir, wherever it is located.
THE HIV RESERVOIR: SPECTRUM OF
VIRAL EXPRESSION, DIVERSITY, AND
REPLICATION COMPETENCY
HIV proviral expression and diversity varies greatly across
cells, tissues, and individuals. Cells with proviruses in their
genomic DNA can increase in frequency (through homeostatic
or antigen-driven proliferation) or decrease in frequency
(through activation-induced cell death, viral cytolysis, or
immune clearance) (Chomont et al., 2009; Wang et al., 2018a).
Importantly, in HIV+ individuals on stable, suppressive ART, the
net effect of the above processes universally result in a very slow
decay of the replication-competent HIV reservoir in resting CD4
T cells (Siliciano et al., 2003; Crooks et al., 2015).
Critically, the exact threshold of viral expression sufficient for
viral cytolysis or immune recognition and clearance is not well
defined. CD4 T cells expressing HIV RNA and sometimes viral
proteins are often detectable in ART-suppressed individuals, in
the absence of any latency reversal intervention (Baxter et al.,
2018). These cells, which represent a portion of provirus that
is competent for viral transcription and translation, may reach
a threshold of viral expression that renders them susceptible to
either immune clearance or cell death. Alternatively these cells
expressing HIV RNA or protein may return to a more quiescent
state and contribute to the maintenance of the HIV reservoir
(Barton et al., 2016; Margolis et al., 2016). Careful definition
of how much viral RNA and/or protein antigen is necessary
to render an infected cell amenable to immune clearance or
apoptosis is needed to inform cure strategies.
In addition to the wide spectrum of viral expression, the HIV
reservoir also contains a large diversity of proviral sequences,
reviewed in van Zyl et al. (2018). This diversity is primarily
attributed to the absence of a proofreading mechanism in the
HIV reverse transcriptase enzyme, as well as high levels of
viremia and recombination (van Zyl et al., 2018). Other factors
that contribute to this diversity include: host immune response
(APOBEC enzyme hypermutations) (Bruner et al., 2016), length
of infection (accumulation of mutations and depletion of CD4
T cell targets) (Arrildt et al., 2015; Zhou et al., 2016), viral
compartmentalization (Yukl and Wong, 2015; van Zyl et al., 2018;
Miller et al., 2019), and selection for viral quasispecies that are
able to evade killing by host immune mechanisms (Phillips et al.,
1991; Wei et al., 2003; Kearney et al., 2009; van Zyl et al., 2018).
Associated with this diversity is a significant frequency of
replication-defective proviruses, as well as clonally expanded
sequences that may or may not be replication-competent (Bruner
et al., 2016; Bui et al., 2017; Wiegand et al., 2017). Critically,
most estimates posit that over 90% of proviruses are replication-
defective. This, combined with the low frequency (0.01–100
per 1,000,000 CD4 T cells) of replication-competent proviruses
(Siliciano et al., 2003; Crooks et al., 2015; Bruner et al.,
2019) makes measurement of the replication-competent HIV
reservoir extremely difficult. Given the diversity of persistent
HIV and large number of defective proviruses, it is critical
to consider what each reservoir assay measures in the context
of the scientific or clinical question being asked, and whether
it overestimates or underestimates the true frequency of the
replication-competent HIV reservoir.
MEASURING THE HIV RESERVOIR
To provide a framework for our review of HIV reservoir assays,
we have organized our discussion into assays that (1) directly
measure proviral genomes (i.e., DNA PCR and DNA sequencing-
based assays) and (2) assays that measure basal or experimentally
inducible persistent HIV expression (i.e., RNA, viral proteins,
or propagating viral infection). The best use of each assay is
dependent on the aims of the scientific study and the type(s) of
samples available (Table 1).
MEASURING THE HIV RESERVOIR:
DIRECT MEASUREMENT OF VIRAL
GENOMES
DNA PCR Assays
One of the first, and to date most widely used methods to estimate
the frequency of persistent HIV is the detection of HIV DNA
by quantitative PCR (qPCR). Of note, these assays all measure
proviruses directly, but do not provide any information about
their inducibility. An economical and rapid method, DNA PCR
assays have been widely applied in different cell types and tissues
(Malnati et al., 2008; Chomont et al., 2009; Yukl et al., 2013).
However, it is often difficult to compare DNA PCR measurements
across different assays (assay performance characteristics and
cell normalization methods), individuals (proviral sequence
heterogeneity) and tissues (differential extraction efficiencies and
levels of PCR inhibitors across tissues) (Henrich et al., 2017).
Specific DNA PCR assays are too numerous to discuss here, but
primarily target conserved regions of gag, the LTR, or pol.
Digital droplet PCR (ddPCR) assays for HIV DNA have also
been developed, and in general relative to qPCR have greater
precision and tolerance for primer/probe mismatches, which are
common because of the sequence heterogeneity of proviral DNA
(Strain et al., 2013; Rutsaert et al., 2018). One limitation of
HIV ddPCR assays, however, is the presence of false positives
in no template control (NTC) wells and in DNA samples from
HIV seronegative participants. This limitation, discussed in detail
elsewhere (Strain et al., 2013; Kiselinova et al., 2014; Bosman
et al., 2015; Rutsaert et al., 2018), is problematic for participants
with very low reservoir frequencies. In contrast, false positives
in qPCR assays occur much less frequently, and false positives
can be excluded by sequencing, which is not possible on current
ddPCR platforms (Strain et al., 2013; Bosman et al., 2015). Thus,
for discriminating the absolute presence or absence of HIV DNA,
qPCR-based approaches are preferred.
qPCR and ddPCR DNA assays overestimate the frequency
of replication-competent reservoir primarily because there are
many mutations with a replication-defective phenotype that














































DNA qPCR/ddPCR (one region) Yes Yes∗∗ No No Low Low Low Over Malnati et al., 2008; Strain et al., 2013;
Bosman et al., 2015
Integrated DNA Assay Yes Yes No Yes Medium Low Medium Over Reviewed in Liszewski et al., 2009
IPDA Yes Yes∗∗ Partial No Low Low Medium Over Bruner et al., 2019
Q4PCR Yes Yes Yes∗ No Medium Low High Over Gaebler et al., 2019
SGS or NGS (one region) Yes Yes No No Medium Low High Over Reviewed in Wang and Palmer, 2018
Near-full length genome
sequencing
Yes Yes Yes∗ No High Medium High Over Ho et al., 2013; Bruner et al., 2016;
Hiener et al., 2017; Lee et al., 2017
Integration site + full
length genome sequencing
Yes Yes Yes∗ Yes High Medium High Over Einkauf et al., 2019; Patro et al., 2019
RNA Bulk cell PCR Yes Yes No N/A Low Low Low Over Archin et al., 2012; Shan et al., 2013
Single cell PCR Yes Yes No N/A Low Low High Over Procopio et al., 2015; Yucha et al., 2017
Single copy assay (SCA) Yes Yes No N/A Medium N/A Medium Over Reviewed in Wang and Palmer, 2018
SGS or NGS Yes Yes No N/A Medium Medium High Over Wiegand et al., 2017; Das et al., 2018
In situ hybridization/RNA
flow
Yes Yes No N/A Medium Medium Medium Over Zhang et al., 2018; Porichis et al., 2014;
Martrus et al., 2016; Baxter et al., 2017;
Grau-Exposito et al., 2017
p24 FAST/Digital Microscopy Yes Partial∗∗∗ Partial N/A High Medium High Over DeMaster et al., 2015
Flow Cytometry Yes Partial∗∗∗ Partial N/A Medium Medium Medium Over Baxter et al., 2016; Martrus et al., 2016;
Baxter et al., 2017; Pardons et al., 2019
ELISA (Digital and
Standard)
Yes Partial∗∗∗ Partial N/A Medium Medium Medium Over Wu et al., 2017
Mass Cytometry Yes Partial∗∗∗ Partial N/A Medium Medium Medium Over Cavrois et al., 2017
Outgrowth QVOA Yes Yes Yes N/A High High High Under Siliciano and Siliciano, 2005; Archin
et al., 2017
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occur outside of the viral region assayed, including APOBEC
hypermutations, insertions, deletions, and packaging signal
defects (Bruner et al., 2015, 2016). In addition, because most
DNA PCR primers are designed inside the HIV genome region,
these assays also detect linear unintegrated DNA and episomal
forms of HIV DNA such 2-long terminal repeat (2-LTR) circles,
though these unintegrated forms are significantly less frequent,
and their stability in durably ART-suppressed individuals is
debated (Eriksson et al., 2013; Bruner et al., 2015; Martinez-
Picado et al., 2018). To overcome the problem of unintegrated
forms of HIV DNA, assays for integrated HIV DNA were
developed, taking advantage of the high frequency (∼11%) of
Alu short interspersed elements within the human genome as
a host target to guarantee the exclusion of unintegrated forms
of HIV (Deininger, 2011). One primer targets Alu elements
while the other primer targets gag, followed by a nested PCR
for the HIV LTR, enabling the detection of integrated provirus
(O’Doherty et al., 2002; Liszewski et al., 2009). However, these
assays are subject to variable efficiency depending on the
proximity of human Alu sequence and the HIV genome that
requires correction, and often require a high number of replicates
for accurate frequency estimation (Liszewski et al., 2009; Graf
and O’Doherty, 2013). Other methods to assay for integrated
HIV DNA, including gel fractionation, inverse PCR, and linker
ligation PCR, are reviewed in Liszewski et al. (2009).
In most PCR assays, the use of primers and probes targeting
only one highly conserved proviral region detect HIV genomes
that are defective or mutated in regions external of the assay
amplicon (Eriksson et al., 2013; Bruner et al., 2016). Recent efforts
have developed assays to simultaneously detect several conserved
regions of the HIV genome. Bruner et al. (2019) developed
the Intact Proviral DNA Assay (IPDA) that, based on ddPCR
multiplex technology, simultaneously interrogate the presence of
an intact packaging signal (PS) and the Rev-responsive element
(RRE) within env. This innovative approach enables estimates
of intact proviral DNA with as few as 5 million CD4 T cells.
Moreover, the IPDA does not depend on long-distance PCR, the
inefficiency of which might limit the ability of near full-length
DNA sequencing approaches to accurately estimate the frequency
of intact provirus. However, because the IPDA detects only a
small sub-genomic region (2% of the HIV genome), there is still a
risk of overestimation of intact proviral DNA. The IPDA may also
quantify possible non-inducible provirus that may permanently
remain latent for the lifetime of an individual. Bruner et al.
(2019), in a bioinformatics analysis of several hundred proviral
sequences, report that of the proviruses that would be amplified
by the IPDA, approximately 70% are intact. To what extent this
percentage varies from participant to participant, however, was
not studied as it was not possible to perform sequencing following
ddPCR in this study.
This knowledge gap was recently addressed by Gaebler et al.
(2019), using a combined quadruplex qPCR and next-generation
sequencing approach, termed Q4PCR. Q4PCR employs probes
for PS, env (RRE), pol and gag that are highly conserved in
intact proviruses. Q4PCR employs the same primer/probe set
for env (RRE) as in the published version of the IPDA as well
as the patent application (Siliciano, 2016; Bruner et al., 2019;
Gaebler et al., 2019). Compared to the published version of the
IPDA (Bruner et al., 2019), the primers for the PS region are
different in Q4PCR (Gaebler et al., 2019); however, the probe is
nearly identical. The PS primers and probe used in Q4PCR are
identical to the sequences in the patent application for the IPDA
(Siliciano, 2016).
Gaebler et al. (2019), in a separate bioinformatics analysis
of >1000 near-full length sequences found that approximately
60% of proviruses detected by the PS and env primer/probe
combination were intact. However, in sequence analysis of six
individuals, they found that no amplification occurred for PS and
env probes in 2/6 individuals. This variability was attributed to
sequence polymorphisms in proviral genomes across individuals.
While a potential issue, it appears to occur relatively infrequently
(Bruner et al., 2019) and is readily corrected with alternative
primers. In four individuals studied by Gaebler et al. (2019),
the percentage of proviruses called intact by the IPDA probes
that were truly intact by near-full-length sequencing varied
from 9.1 to 96%. Gaebler et al. (2019) findings highlight a
potential limitation of the IPDA: the percentage of proviruses
that are correctly called intact by the IPDA may vary widely
between individuals. This may be less troublesome if the assay
is used to measure the effect of an intervention in an individual,
but problematic if the assay is used to categorize different
individuals. Further evaluation of more individuals with head-to-
head comparisons of the Q4PCR method (modified to include
the most current version of the IPDA PS primer sequences)
and the IPDA is warranted. Moreover, development of intact
proviral DNA assays that are optimized for all HIV subtypes
will be necessary (Bruner et al., 2019). Nonetheless, the IPDA
represents an attractive addition to the reservoir assay toolkit,
as it is currently the most accurate high-throughput DNA assay
for estimating the size of the replication-competent reservoir
(Bruner et al., 2019).
HIV DNA Sequencing
Sequencing of HIV proviral genomes enables measurements
of reservoir frequency, diversity, and evolution. While single
genome/proviral sequencing (SGS/SPS) assays provide important
information about proviral diversity, they overestimate the
replication competent reservoir because they are based on
sequencing of subgenomic regions and miss proviruses with
deletions or mutations in the primer binding sites (Wang and
Palmer, 2018). To reduce the former limitation, several near full-
length HIV sequencing assays were developed (Ho et al., 2013;
Bruner et al., 2016; Hiener et al., 2017; Lee et al., 2017) and are
reviewed in Wang and Palmer (2018) and Wang et al. (2018b).
Although laborious and expensive, they provide an assessment of
persistent HIV diversity across different cell subsets and tissues,
and with longitudinal sampling, could provide insight into the
dynamics of reservoir frequency and diversity over time (Hiener
et al., 2017; Lee et al., 2017). Limitations of these near-full-
length sequencing assays include poor coverage of the viral LTRs
and slight overestimation of replication-competent reservoir
frequency (Wang and Palmer, 2018; Einkauf et al., 2019). In
addition, application of these technologies to a higher number
of individuals and time points is necessary to make generalizable
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findings about the sequence composition of the HIV reservoir
(Wang et al., 2018b).
Sequencing of HIV integration sites has also provided critical
insights into the HIV reservoir. Initial integration site mapping
efforts underscored the importance of clonal expansion in HIV
reservoir maintenance (Maldarelli et al., 2014; Wagner et al.,
2014). Simultaneous detection of near-full length provirus as
well as its integration site could improve knowledge of the
reservoir and inform cure strategies. Two research groups are
developing integrated full length HIV sequencing assays capable
of linking HIV genome sequences and their integration site.
Both the methods use a multiple displacement amplification
(MDA) combined with SGS (Full length integrated proviral single
genome sequencing, FLIP-SGS) (Patro et al., 2019) or followed
by NGS (matched integration site and proviral sequencing, MIP-
Seq) (Einkauf et al., 2019). These methods may yield important
insights into reservoir dynamics and formation, as well as
reservoir maintenance through clonal expansion. Early studies
suggest that in participants on durable therapy, intact proviruses,
relative to defective proviruses, are enriched in non-genic regions
of the genome (Einkauf et al., 2019).
MEASURING THE HIV RESERVOIR:
ASSESSMENT OF BASAL OR
INDUCIBLE RESERVOIR EXPRESSION
Cell-associated HIV RNA is readily detectable at baseline, even
in resting CD4 T cells (Archin et al., 2012; Archin et al., 2017).
This suggests that at least in some cells, HIV is not completely
quiescent. Thus, measurements of persistent HIV can be made on
(1) unstimulated cells or (2) cells stimulated with T cell activating
agents (the inducible reservoir). It is important to note for assays
that measure the inducible reservoir, whether at the level of
RNA, protein, or viral outgrowth, not all replication-competent
proviruses are induced by a single round of T cell activation
(Ho et al., 2013).
HIV RNA PCR
While proviruses that are transcription-competent are more
likely to be replication-competent than any given sample of
proviral DNA, there are still many defective proviruses that can
be expressed at the RNA level (Bruner et al., 2016; Imamichi
et al., 2016; Pollack et al., 2017; Wiegand et al., 2017). That said,
baseline ca-RNA expression (and bulk HIV DNA) is predictive
of time to viral rebound upon therapy cessation and may serve
as a biomarker to guide future analytical treatment interruption
studies (Pasternak and Berkhout, 2018).
Unlike proviral DNA where there is (generally) one integrated
copy per infected cell, many copies of RNA can be present in
a single cell, which makes reservoir frequency measurements
using RNA more challenging. Bulk qPCR or ddPCR assays of
HIV RNA can provide a sensitive and low cost estimation of
HIV transcription. Of note, for one reported HIV-RNA assay,
semi-nested qPCR appeared to have greater quantitative linearity,
accuracy, and sensitivity relative to ddPCR (Kiselinova et al.,
2014). However, these assays of bulk RNA cannot determine
the frequency of HIV RNA positive cells, or the phenotype of
the cell(s) expressing HIV RNA. Furthermore, similar issues
discussed above in the DNA PCR section for comparisons across
assays, individuals, and tissues apply to RNA as well. Targets
of cell-associated RNA assays include assays for unspliced gag
(Archin et al., 2012), polyadenylated transcripts (Shan et al.,
2013), among others (Fischer et al., 2002; Pasternak et al., 2013;
Pasternak and Berkhout, 2018). In addition, Yukl et al. (2018)
recently published a ddPCR assay for multiple HIV transcripts
(read-through, TAR, elongated, spliced, etc.) which may yield
insights into the nature of blocks to HIV transcription from the
reservoir at baseline or in response to latency reversal agents.
Inducible HIV cell-free RNA from culture supernatants can also
be measured (Spivak et al., 2015). Furthermore, measurements
of residual viremia from individuals on suppressive ART using
ultrasensitive single-copy HIV RNA assays (SCA) may serve as a
measurement of inducible persistent HIV, as this residual viremia
may reflect persistent HIV that is expressed following T cell
activation due to normal immune physiology. SCA have limits
of detection of 1 copy/mL of plasma (or lower, depending on
the volume of plasma used), and have been used to study ART
treatment intensification and latency reversal in clinical studies
(reviewed in Wang and Palmer, 2018).
Other RNA PCR approaches have been developed to estimate
the frequency of RNA expressing reservoir cells. Limiting dilution
single cell RNA PCR assays estimate the frequency of HIV cell-
associated RNA expressing cells (Pasternak and Berkhout, 2018).
A major limiting dilution assay is the Tat/rev induced limiting
dilution assay, or TILDA (Procopio et al., 2015). By assaying
multiply spliced HIV RNA, TILDA assay reduces reservoir
frequency overestimation because multiply spliced HIV RNA
is less likely to (but still may) have replication defects than
DNA measurements (Procopio et al., 2015; Imamichi et al.,
2016; Pollack et al., 2017). Another innovative approach for
estimating the frequency of RNA-expressing cells is single cell
ddPCR (Yucha et al., 2017). Of note, all of these assays require
further cross-sectional and longitudinal validation, to determine
if they can categorize individuals in a useful way, or if they
have appropriate discriminatory power to register the effect of a
reservoir depletion strategy over time.
HIV RNA Sequencing
Limiting dilution sequencing assays have been developed, but
are restricted by cost and sequence coverage. However, these
assays are able to estimate the number of RNA copies per cell
in addition to the frequency of RNA-expressing cells (Pasternak
and Berkhout, 2018). Wiegand et al. (2017) developed the
cell-associated HIV RNA and DNA single-genome sequencing
(CARD-SGS) assay to estimate the frequency of HIV proviruses
that express RNA at baseline. In addition, Das et al. (2018)
recently reported a multi spliced RNA assay called EDITS
(envelope detection by induced transcription-based sequencing)
based on RT-nested PCR amplification of multiply spliced env
RNA followed by NGS.
The sequencing of HIV RNA by SGS/NGS has been performed
in several experimental contexts. SGS remains the gold standard
even though it is expensive and time consuming. The use of
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NGS, however, is limited. The frequency of PCR errors, PCR
bias, recombination and rearrangement that occurs during NGS
library construction need to be carefully considered. Methods
such as primer ID (Jabara et al., 2011; Zhou et al., 2015) and
alternative adaptor attachment strategies (Boltz et al., 2016) can
mitigate the errors associated with NGS library preparation.
HIV RNA Staining Assays
In situ hybridization (ISH) of RNA at the single cell level
was developed in the 1990s, and subsequently modified to
simultaneously detect HIV RNA and host or virus RNA or
protein (Wong et al., 1997a; Schacker et al., 2000; Baxter et al.,
2018; Deleage et al., 2018). The development of these assays
is reviewed elsewhere (Baxter et al., 2018). We highlight the
recent development of next-generation HIV ISH assays, such as
RNAscope and FISH-flow, that enable the detection of single
HIV RNA positive cells with microscopy visualization (Estes
et al., 2017; Zhang et al., 2018) or flow cytometry (Porichis et al.,
2014; Martrus et al., 2016; Baxter et al., 2017; Grau-Exposito
et al., 2017). Using these techniques, some inference about the
levels (copies) of RNA per cell can be made based on staining
intensities, in addition to the frequency of HIV RNA-expressing
cells. A novel multiplex microscopy ISH approach allows for
detections of viral DNA, RNA and protein. However, this has
yet to be evaluated in cells from ART-suppressed participants
(Puray-Chavez et al., 2017).
HIV gag p24 Assays
Recent efforts in the cure field have developed assays to quantify
baseline or inducible expression of viral proteins, in particular
the p24 capsid protein in whole cells. The rationale behind this
effort is that quantification of inducible viral protein reduces
overestimation of the frequency of the replication-competent
reservoir, as proviruses that can progress through transcription
and translation are less likely to have major defects (Bruner et al.,
2016). All assays that employ antibodies to p24 are limited by
a false positive rate from non-specific antibody binding. The
use of two p24 antibodies may, at least partially, overcome
this limitation.
Graf et al. (2013) demonstrated that in ART-suppressed
participants, gag protein positive cells could be detected at a
frequency of ∼1 gag+ cell per million PBMCs. This finding
supported the notion that at baseline, some persistent HIV is
expressed at a protein level. However, this technique had a high
false positive rate. To mitigate false positives, groups endeavored
to detect gag positive cells in tandem with CD4 downregulation,
suggestive of the presence of the Nef protein. O’Doherty and
colleagues used a combination of Fiber-optic Array Scanning
Technology (FAST) and automated digital microscopy to detect
gag positive with concomitant CD4 downregulation, suggesting
the presence of actively transcribed and translated viral proteins
(DeMaster et al., 2015). While this technology improved the
false positive rate, it is not yet widely used. Other groups
focused on honing the specificity of p24 flow cytometry assays.
The combination of gag staining with RNA flow (discussed
above) proved useful in some trials but not others, likely due
to RNA sequence heterogeneity (Baxter et al., 2016, 2017;
Martrus et al., 2016; Grau-Exposito et al., 2017). Using a
high number of RNA probes resulted in robust detection of
gag+RNA+ cells, with the expected CD4 downregulation and
enrichment in cell populations such as Tfh and PD1+ cells
(Baxter et al., 2016, 2017, 2018).
More recent efforts have focused on using two gag protein
probes in flow cytometry application to quantify inducible
persistent HIV at the protein level. Chomont and colleagues
recently published a flow cytometry protocol that utilizes two
capsid antibodies for dual intracellular staining of p24 (Pardons
et al., 2019). In ART-suppressed individuals, p24 double positive
cells correlated with TILDA and QVOA measures. However, in
this study, no p24 double positive cells were detected in ART-
suppressed participants at baseline, in contrast to previous work
using a single p24 antibody (Graf et al., 2013; Baxter et al., 2016).
Notably, this novel technology might permit characterization of
reservoir cells from ART-suppressed donors using standard flow
cytometry surface markers and intracellular staining.
Another focus in quantification of viral reservoirs has utilized
digital ELISA technology to quantify the very low levels of p24
produced from CD4 T cells after stimulation with a latency
reversal agent or global T cell activator. This assay can be applied
to cell lysates or culture supernatants and is able to detect
sub-femtomolar levels of p24; however, the correlation of these
measures with other assays of persistent HIV infection is not yet
fully assessed (Wu et al., 2017).
Finally, high parameter mass cytometry techniques using
heavy-metal tagged antibodies have been applied to in vitro
studies of HIV infection to phenotype tonsillar CD4 T cells
infected with a mass-cytometry compatible reporter virus
(Cavrois et al., 2017). Assays to detect HIV p24 using mass
cytometry are an area of active investigation and development.
OUTGROWTH ASSAYS
HIV Outgrowth Assays
Significant effort has been deployed recently to develop new
or improved assays to measure clinical interventions aimed
at depleting the HIV replication-competent reservoir. While
assays based on PCR of HIV DNA offer a streamlined method
to quantitate persistent HIV infection, a significant fraction
of persistently infected cells harbor defective proviruses that
cannot be distinguished from replication-competent provirus
by amplification of one genomic region (Eriksson et al., 2013;
Ho et al., 2013; Bruner et al., 2016). Thus, approaches to
eradicate HIV infection will likely need to incorporate assays
that reflect depletion of replication-competent viruses to measure
the efficacy of anti-latency therapeutics. The quantitative viral
outgrowth assay (QVOA or simply VOA) is probably the most
well-known assay used to quantitate replication-competent HIV.
During the early days of the HIV epidemic, co-culture
assays of PBMC from HIV-infected individuals with
Phytohaemagglutinin (PHA)-stimulated PBMC from uninfected
donors were used to confirm the presence of replicating virus
and provide an estimation of the viral burden within infected
people (Castro et al., 1988; Jackson et al., 1988; Ho et al., 1989;
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Dimitrov et al., 1990). As it became evident that resting CD4
T cells were a major source of integrated proviral DNA during
therapy (Chun et al., 1995), a derivative of these earlier co-culture
assays was developed to quantify replication-competent HIV
in purified CD4 T cells from HIV-infected individuals (Finzi
et al., 1997; Wong et al., 1997b; Siliciano and Siliciano, 2005).
Several detailed protocols for the traditional QVOA are available
(Siliciano and Siliciano, 2005; Laird et al., 2016; Archin et al.,
2017). Highly purified total or resting CD4+ T-cells are isolated
from whole blood, leukapheresis product, or tissue-derived
mononuclear cells for QVOA, and are stimulated with mitogen
and co-cultured in a limiting dilution format with PHA-activated
CD8-depleted PBMCs from HIV-seronegative individuals to
exponentially expand the virus. Supernatant from co-culture
assays are then assessed for the presence of p24 protein and
Poisson statistics applied to estimate the frequency of resting
cell infection that is reported as infectious unit per million
CD4+ T cells (IUPM).
The QVOA is considered the gold standard for measuring
replication-competent HIV and provides a definitive minimal
estimate of reservoir size. However, the assay is costly and labor
intensive, and given the low frequency of latently infected cells,
often large numbers of cells are required to increase the limit
of detection. The QVOA reports a minimal estimate of the
frequency of latent but replication-competent proviruses, due
to the presence of “non-induced” proviruses unresponsive to a
single round of cell stimulation (Ho et al., 2013; Hosmane et al.,
2017). Despite its limitations, the QVOA remains a reproducible
and reliable method to measure the HIV latent reservoir and has
been used to accurately assess the stability the reservoir over time.
Using the QVOA, we measured resting CD4+ T-cell infection
(RCI) in 37 HIV+ participants, on stable suppressive ART who
donated resting CD4+ T cells via leukapheresis, over a period
of 6 years and found that despite the long duration of ART, the
half live of the reservoir in resting CD4+ T cells to be about
43 months, a value that is very close to that reported by Siliciano
et al. (2003) a decade earlier, using an earlier version of the
QVOA in a clinical cohort 10 years prior, on older ART (Crooks
et al., 2015). This highlights (1) the stability of the replication-
competent reservoir and (2) the reliability of the QVOA to probe
reservoir dynamics.
Given the importance of the QVOA in assessing
replication-competent HIV, many laboratories have introduced
modifications to the original assay to streamline the assay
and improve upon throughput, sensitivity and dynamic range
(Avalos et al., 2016; Laird et al., 2016; Charlins et al., 2017;
Fun et al., 2017; Metcalf Pate and Blankson, 2017; Sanyal et al.,
2017; Massanella et al., 2018; Rosenbloom et al., 2019) (Table 2).
Examples of modifications made to the standard QVOA to
streamline and improve sensitivity involved replacing the
uninfected donor PHA-blasts normally used in the co-culture to
expand virus, with cell lines permissive for HIV infection such
as the MOLT-4/CCR5, or using RT-PCR with primers specific
for polyadenylated HIV-1 or gag RNA to detect virus released
into culture supernatant (Laird et al., 2013; Massanella et al.,
2018). In their mQVOA assay Massanella et al. (2018) also use
the MOLT-4/CCR5 to propagate virus, but used immobilized
CD3/CD28 beads to stimulate CD4 T cells and captured cell
free RNA from the supernatant using magnetic beads before
assaying HIV gag by PCR. In a recent cross-laboratory reservoir
assay validation study (RAVEN), the above modification was
reported to generate IUPM values that were 9.2 fold higher
than traditional QVOA assays as RNA detection was thought to
be more sensitive than p24 measurements (Rosenbloom et al.,
2019). However, while PCR measurements as readout for the
QVOA may provide more sensitivity, the potential that some of
the RNA (even though released into the supernatant) detected
could come from defective provirus, is not full length, and/or
is not part of a viral particle should be taken into consideration
(Pollack et al., 2017). RNA detection may also inherently be
more prone to false positive detection due to low-level PCR
product contamination.
The introduction of ultra-sensitive p24 assay platforms have
ushered in additional methods to quantitate latent HIV with
improved sensitivity of antigen detection in culture supernatant
(Descours et al., 2017; Passaes et al., 2017; Wu et al., 2017).
We have developed a modified QVOA, the Digital ELISA Viral
Outgrowth or DEVO assay that takes advantage of the recently
developed SIMOA platform (Quanterix), capable of femtogram
detection of HIV p24 protein in contrast to the picogram
limitations of traditional ELISA. In this assay, 8–10 × 106
purified resting CD4+ T cells from aviremic, ART-treated
HIV+ participants are PHA stimulated in limiting dilution in
a 96 well-format. With this assay we found that virus can be
expanded using either the CD4 T cell input (i.e., addition of
exogenous donor cells is not necessary), PHA blasts from an
uninfected donor, or HIV permissive cell lines such as the
MOLT4/CCR5. Furthermore, with the DEVO assay we obtained
IUPM comparable or higher than the traditional QVOA at an
earlier time point, thus reducing the overall length of the assay
(Archin et al., 2018).
Finally, another modification of the QVOA reported recently
involves differentiating the input memory CD4+ T cells into
effector memory T cells before activation. On average, higher
IUPM values were observed with the differentiated QVOA
(dQVOA) compared to traditional QVOA assay methods
(Wonderlich et al., 2019). This suggests that induction into the
effector state prior to activation facilitates more efficient exit from
latency (Kulpa et al., 2019).
REDUCING THE RESERVOIR: STABILITY
AND MEANINGFUL REDUCTION
For studies that aim to deplete the reservoir, it is critical to
understand how specific reservoir assay measurements (HIV
DNA, QVOA, etc.) change over time on suppressive therapy
without any cure intervention. Studies of reservoir stability to
date have employed both bulk and intact DNA PCR (PBMCs,
peripheral CD4 T cells) (Besson et al., 2014; Laanani et al., 2015;
Bachmann et al., 2019; Bruner et al., 2019) and viral outgrowth
(peripheral CD4 T cells) (Siliciano et al., 2003; Crooks et al.,
2015). Generally, in peripheral blood CD4 T cells, QVOA and
IPDA reservoir measurements have similar decay kinetics (t1/2
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TABLE 2 | Overview of modified qVOA assays.
Assay Name Modification/Format Readout Reference(s)
QVOA2 PHA+ sero-negative γ-irradiated PBMC stimulation of resting CD4+ T cells;
MOLT4/CCR5 or SupTl-CCR5 as targets for virus expansion
PolyA RNA qPCR or p24 ELISA Laird et al., 2013; Fun
et al., 2017
TZA CD3/CD28 stimulated CD4+ T cells are co-cultured with TZM-bl indicator cells B-gal activity by chemiluminescence Sanyal et al., 2017
dQVOA Resting CD4+ T Cells are differentiated to effector memory phenotype before
activating with PHA + seronegative γ-irradiated PBMC; no targets added
p24 ELISA Wonderlich et al., 2019
mQVOA Immobilized CD3/CD28 simulation of CD4+ T cells; MOLT4/CCR5 targets; cell
free RNA in supernatant captured by magnetic beads
gag or pol RNA qPCR Massanella et al., 2018;
Rosenbloom et al., 2019
Murine VOA
(mVOA)
CD4+ T cells or PBMC from aviremic donors engrafted into immunodeficient
NSG mice, followed by administration of anti- CD3/CD28 and anti-CD8
antibodies
Plasma HIV RNA detection (gag
primers) by qPCR
Metcalf Pate et al., 2015
Humanized mouse
VOA (hmVOA)
CD3/CD28 stimulated resting CD4 T cells from aviremic donors are engrafted
into humanized mice
Plasma HIV RNA detection (LTR
primers) by qPCR
Charlins et al., 2017
M8-QVOA Myeloid cells from SlV-infected macaques are stimulated with TNF-α;
co-cultured with CEMX174 as targets
SIV gag RNA qPCR Avalos et al., 2016
∼44 months) (Bruner et al., 2019). Measures of bulk DNA or
non-intact provirus are more variable in stability (Besson et al.,
2014; Laanani et al., 2015; Bachmann et al., 2019; Bruner et al.,
2019). Within tissues, little is known about reservoir stability
because of the difficulties with accessing tissues, especially over
multiple time points in human participants. Therefore, thorough
understanding of the reservoir stability within tissue may depend
primarily on animal models (Henrich et al., 2017).
In addition to reservoir stability, understanding inter-assay
variability and the error associated with each measurement
is essential to robustly assess potential reservoir reductions.
For instance, evaluation of longitudinal QVOA data suggests
that a sixfold decline in the frequency of resting CD4 T cell
infection would be necessary to achieve 95% confidence that the
intervention resulted in the reduction of the reservoir observed
(Crooks et al., 2015). For other assays, however, the decline
in persistent HIV frequency to achieve 95% confidence of a
reservoir reduction is unknown, and further complicated by
the presence of large frequencies of non-intact proviruses. The
IPDA is a promising assay to assess reservoir reductions in a
high-throughput manner; however, this must be tempered with
concerns about interindividual variability for false positive non-
intact proviruses and the need for further understanding of the
stability and reproducibility of the IPDA over multiple time
points and across diverse human cohorts (Bruner et al., 2019;
Gaebler et al., 2019).
There is also rationale to conduct bulk measures of HIV
provirus (i.e., DNA PCR of a conserved region of a viral gene)
to assess the effect of reservoir reduction interventions on
global levels of HIV DNA. Although >90% of HIV provirus
is replication-defective, a significant portion of proviruses can
express viral proteins that may contribute to chronic immune
activation and sequelae (Hunt et al., 2016; Imamichi et al., 2016;
Pollack et al., 2017). Therefore, information about the effect of
interventions on total persistent HIV frequency may be useful.
At the same time, however, defective provirus may be more
resistant to latency reversal and immune clearance interventions
because of lower expression of viral RNA and/or protein. If this
is the case, reservoir assays that measure intact proviruses, viral
RNA/proteins, or replication-competent HIV may have a higher
sensitivity to potential reservoir reductions.
For experimental medicine trials, we propose a framework
where the more costly and labor intensive QVOA-based measures
are employed at study beginning and as primary end points,
with more intensive readouts of genetically intact DNA, bulk
DNA, and/or other reservoir measurement occurring both at the
start and end, as well as throughout the trial. Our reasoning
behind this recommendation is that QVOA provides a direct
measure of replication-competent virus that could re-establish an
infection, whereas DNA and other assays all have concerns about
detection of replication-deficient virus. Moreover, for QVOA,
there is a defined magnitude of decline (sixfold) in reservoir
frequency necessary to attribute a reservoir reduction to a specific
intervention (Crooks et al., 2015), whereas for other assays this
magnitude of reduction is unclear. In addition, for potential
cures, it will be essential to show by QVOA-based methods over
multiple time points the absence of replication-competent virus
recovery. The engraftment of CD4+ T cells from individuals
who are negative by QVOA into murine viral outgrowth models
(mVOA or hmVOA, Table 2) could be used as additional metrics
to ascertain the absence or reduction of replication competent
virus (Metcalf Pate and Blankson, 2017).
At the same time, however, standard QVOA based
measurements only provide a definitive minimal estimate
of reservoir frequency, likely because of the presence of non-
induced proviruses (Ho et al., 2013). Concomitant use of
the IPDA overcomes this limitation because measurement of
genetically intact provirus is not dependent on the transcriptional
status of the cell, and may provide a maximal estimate of
replication-competent provirus. Further, other reservoir
measurements such as the IPDA or other assays described
herein may afford a greater dynamic range and sensitivity to
reservoir reductions, though this remains to be proven. As there
is growing evidence for the clonality of the HIV reservoir, novel
full length sequencing approaches with integration site analysis
will permit the assessment of the impact of interventions on
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the clonality of the reservoir. Taken together, the combination
of primary endpoint QVOA-based reservoir measures with more
intensive, higher throughput evaluation of the reservoir using the
IPDA, bulk DNA, inducible reservoir measurement(s), and/or
sequencing approaches will enable a thorough evaluation of
the impact of any intervention on persistent HIV in cure
research trials.
SUMMARY
Assays to measure persistent HIV infection are emerging
quickly. Key issues for the cure field with regard to reservoir
assay development include (1) optimization of viral outgrowth
assays for reproducibility, sensitivity, and dynamic range,
(2) further understanding of interindividual variability in false
positive intact proviruses and stability over time for the
IPDA, (3) additional development of full-length/integration site
sequencing approaches to understand proviral dynamics during
therapy or potential interventions, and (4) advancement of
DNA/RNA/p24 single and/or multiplex detection methods to
better understand the dynamics and mechanisms of latency
reversal with different agents.
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